ClinicalTrials.gg
CompletedNCT02567799NSCLCUpdated Jan 25, 2024Results posted

BIO 300 Non-Small Cell Lung Cancer Study

A Phase 1/2 interventional study of BIO 300 Oral Suspension and Paclitaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Humanetics Corporation. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Humanetics Corporation · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
2,263rd of 2,995
21 · median 56
Started
2015
with 169 others
Phase 1/2
484 of 3,368
117 open now
Registered
1,604th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,263rd largest by enrollment of the 2,995 interventional ones that give a count, is one of 170 that started in 2015, is one of 484 in phase 1/2, and was the 1,604th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral Suspension when used in combination with standard dose radiation therapy and chemotherapy in patients with non-small cell lung cancer. Based on preclinical data the investigators hypothesize that BIO 300 Oral Suspension will reduce the incidence of radiation-induced pneumonitis and pulmonary fibrosis.

Read the detailed description

This is an open-label, single-arm, ascending dose Phase I/II study of BIO 300 Oral Suspension given in combination with paclitaxel/carboplatin and radiotherapy in subjects with stage II, III, or IV NSCLC who are candidates for combined chemoradiotherapy.

A minimum of 6 subjects will be accrued sequentially at each dose level of BIO 300. BIO 300 will be administered daily for the entire course of concurrent chemoradiotherapy, a minimum of 6 weeks; in combination with standard paclitaxel / carboplatin chemotherapy and radiotherapy.

The initial dose of BIO 300 will be administered on Day 1, Visit 2 in which safety data (adverse events, electrocardiograms (ECGs), results of safety laboratory determinations), pharmacokinetic (PK) and pharmacodynamic (PD) data will be collected. PK data will be collected from a minimum of six (6) study subjects from each cohort. PD data will be collected from all subjects in each study cohort. Day 1 of chemotherapy will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 1 day of BIO 300 dosing. BIO 300 will be administered in combination with the chemotherapy components of the protocol (paclitaxel and carboplatin). During the first or second chemotherapy infusion, additional safety, PK and PD data will be collected. Day 1 of radiation therapy (RT) may be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. BIO 300 will continue to be administered daily; paclitaxel and carboplatin will be administered weekly and radiotherapy will be administered daily until a total dose of 60-70 Gy has been administered. During the period of combined BIO 300 and chemoradiotherapy (6-7 weeks), additional safety, PK and PD data will be collected weekly. An interim data analysis will be completed once the highest dose cohort concludes chemoradiation therapy, in an effort to determine the optimal biological dose. Following analysis, there will be an option to enroll up to an additional 12 subjects at the optimal biological dose. At the conclusion of the study, primary and secondary outcome measures will be evaluated. Data will be analyzed from all cohorts to determine the oncologic response, safety of BIO 300, and a recommended BIO 300 dose.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Lung Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological or cytological confirmation of NSCLC
  2. Stage II, III, or IV NSCLC for whom radiation therapy of 60 Gy and concurrent weekly paclitaxel/carboplatin is recommended
  3. Up to three small (≤ 3 cm each) lung oligometastases will be allowed and/or one oligometastasis at any other site in the body
  4. Performance Scale (ECOG PS) of 0 or 1
  5. Forced expiratory volume at one second (): best value obtained pre- or post-bronchodilator must be ≥ 1.0 liters/second or > 50% predicted value
  6. Adequate bone marrow reserve
  7. Adequate hepatic reserve
  8. Adequate renal function
  9. Female subjects of must have a negative pregnancy test
  10. Female subjects of childbearing potential and male subjects with female sexual partners of childbearing potential must agree to use an effective method of
  11. Ability to read and provide written

Exclusion criteria

Exclusion Criteria:

  1. Weight loss greater than 10% in prior 4 weeks
  2. Prior in which they received any thoracic radiotherapy unless the treating physician considers it unlikely to impact the clinical outcome of the patient
  3. Patients with concurrent invasive malignancy other than non-melanoma skin cancer or cervical intraepithelial neoplasia unless the treating physician considers it unlikely to impact the clinical outcome of the patient
  4. An active infection or with a fever ≥ 38.5°C
  5. Poorly controlled intercurrent illnesses
  6. Patients with a prior thoracotomy within 1 week of study registration
  7. (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration
  8. Patients with any of the following are not eligible:

    • Previous history of Interval (QTc ) prolongation resulting from medication that required discontinuation of that medication
    • Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age;
    • Presence of left bundle branch block (LBBB);
    • QTc with Fridericia's correction that is unmeasurable, or ≥ 480 msec on screening . The average QTc from the screening ECG (completed in triplicate) must be \< 480 msec in order for the patient to be eligible for the study;
    • Subjects taking any concomitant medication that may cause QTc prolongation, induce Torsades de Pointes are not eligible if QTc ≥ 460 msec.
  9. Patients must not have had a cardiac event within 6 months before entry; or the presence of any other uncontrolled cardiovascular conditions that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
  10. Patients with a history of arrhythmia or asymptomatic sustained ventricular tachycardia are not eligible. Patients with atrial fibrillation with well-controlled ventricular rate on medication, are eligible.
  11. Psychiatric conditions, social situations or substance abuse that precludes the ability of the subject to cooperate with the requirements of the trial and protocol therapy
  12. Grade 2 or higher peripheral neuropathy
  13. Known history of /Acquired Immune Deficiency Syndrome (HIV/AIDS), or C.
  14. Pregnancy or women of and men who are sexually active and not willing/able to use medically acceptable forms of
  15. Women who are breastfeeding are not eligible for this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Single-arm

    Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.

    Drug: BIO 300 Oral Suspension · Drug: Paclitaxel · Drug: Carboplatin · Radiation: Radiotherapy

Interventions

  • Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.

    Also known as: genistein, 5, 7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one

  • During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6. During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart.

    Also known as: Onxol, Taxol

  • During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6. During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart.

    Also known as: Paraplatin, CARBOplatin Novaplus

  • RadiationRadiotherapy

    Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With BIO 300 Oral Suspension-related Dose Limiting Toxicity

    Adverse events of CTCAE v4.0 grade 3 or higher that were possibly, probably or definitely related to BIO 300 Oral Suspension and have occurred before or during concurrent chemoradiotherapy were considered dose limiting toxicities.

    Time frame: Day 1 up to 6 weeks or maximum tolerated dose

Secondary outcomes

  1. Number of Participants With Adverse Events Throughout the Study

    Time frame: Day 1 up to month 13 post radiation or 12 months post chemotherapy consolidation for surgical participants.

  2. Mean Maximum Serum Concentration (Cmax) of BIO 300 Administered in the Absence of Chemotherapy

    Time frame: Day 1, prior to 1st dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post dose

  3. Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 Administered in the Absence of Chemotherapy

    Time frame: Day 1, prior to 1st dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post dose

  4. Mean Maximum Serum Concentration (Cmax) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin

    Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to 1st dose then 0.5, 1, 2, 3, 4, 8, and 24 hours post dose

  5. Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin

    Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to 1st dose then 0.5, 1, 2, 3, 4, 8, and 24 hours post dose

  6. Mean Maximum Serum Concentration (Cmax) of Paclitaxel When Administered in Combination With BIO 300

    Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose

  7. Mean Area Under the Serum Concentration Curve (AUC) of Paclitaxel When Administered in Combination With BIO 300

    Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose

  8. Mean Maximum Serum Concentration (Cmax) of Carboplatin When Administered in Combination With BIO 300

    Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose

  9. Mean Area Under the Serum Concentration Curve (AUC) of Carboplatin When Administered in Combination With BIO 300

    Time frame: Week1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose

  10. Percent Change From Baseline in Expression Levels of Serum TGF-beta Isoform 1 (TGFB1)

    Measuring change from baseline (screening visit) of TGF-beta isoform 1 (TGFB1)

    Time frame: Screening, once weekly during weeks 1-6 of concurrent chemoradiotherapy prior to BIO 300, paclitaxel, and carboplatin dose, and once at the end of consolidation, 3 months and 6 months after the completion of RT

  11. Rate of Progressive Disease Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) (1.1) Criteria

    Best Response Rate reported per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by chest CT imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), At least a 20% increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Screening, visits 20, 37, 38, 39, 40, 41 & 42 (through visit 41 for surgical participants)

  12. Change in Tumor Diameter as Measured by Diagnostic Computerized Tomography (CT) Scan

    Tumor diameter was measured in centimeters. Mean change in tumor diameter from the baseline measurement at screening is reported.

    Time frame: Screening, visits 20 and 3, 6, 11 & 13 months post radiation therapy

  13. DLCO as Measured by Pulmonary Function Test (PFT)

    Time frame: Screening and months 6 & 13 post radiation therapy completion

  14. Number of Participants With Pulmonary Fibrosis Assessed by Four-dimensional Computerized Tomography (4D-CT)

    Time frame: Screening, visits 20 & 37 and 9 & 13 months post radiation therapy for non-surgical participants; screening only for surgical participants

  15. Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) Patient Reported Outcome Questionnaire.

    The Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) questionnaire is a 36-item self-reporting instrument that measures quality of life specific to patients with cancer. Items are rated on a 5 item (point) Likert Scale, from 0 (not at all) to 4 (very much). Total scores range from 0 to 136 and higher scores indicate better quality of life. The FACT-L TOI questionnaire was scored according to FACT-L Scoring Guidelines Version 4.

    Time frame: Screening and months 3, 6, & 13 post radiation therapy completion

  16. Quality of Life (QOL) as Measured by University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Patient Reported Outcome Questionnaire.

    The UCSD-SOBQ is a 24-item patient self-reported questionnaire where items are scored on a 6-point scale (0, "not at all" to 5, "maximal or unable to-do because of breathlessness"). Total scores range from 0 to 120 and lower scores indicate better quality of life.

    Time frame: Screening and months 3, 6, & 13 post radiation therapy completion

  17. Extent of Esophagitis by Patient Reported Swallowing Diary

    The assessment will provide a score (the swallowing questionnaire) from 0 to 5; 1 no problems swallowing; 2 mild soreness only; 3 some difficulty swallowing solids; 4 cannot swallow solids; and 5 cannot swallow liquids.

    Time frame: Screening, weeks 1, 2, 3, 4, 5, & 6 and months 3 & 6 post radiation therapy completion

  18. Mean Weekly BIO 300 Trough Levels, Serum Concentration of BIO 300

    Time frame: Concurrent chemoradiotherapy weeks 1, 2, 3, 4, 5 and 6

  19. Weekly Paclitaxel Trough Levels, Plasma Concentration of Paclitaxel and Carboplatin

    Serum trough levels of paclitaxel and carboplatin were measured. Carboplatin trough levels were below the limit of quantification at all timepoints and are therefore reported as NA (Not Available).

    Time frame: Concurrent chemoradiotherapy weeks 1, 2, 3, 4, 5 and 6

  20. FVC as Measured by Pulmonary Function Test (PFT)

    Time frame: Screening and months 6 & 13 post radiation therapy completion

  21. FEV1 as Measured by Pulmonary Function Test (PFT)

    Time frame: Screening and months 6 & 13 post radiation therapy completion

07

Results

Posted Dec 20, 2023

Participant flow

Concurrent Chemoradiotherapy
Participant flow — Concurrent Chemoradiotherapy
MilestoneBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Started777
Completed646
Not completed131
Withdrew: Death100
Withdrew: Adverse event010
Withdrew: Progressive disease021
Follow-up
Participant flow — Follow-up
MilestoneBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Started646
Completed432
Not completed214
Withdrew: Death101
Withdrew: Progressive disease113

Outcome measures

PrimaryNumber of Participants With BIO 300 Oral Suspension-related Dose Limiting Toxicity

Adverse events of CTCAE v4.0 grade 3 or higher that were possibly, probably or definitely related to BIO 300 Oral Suspension and have occurred before or during concurrent chemoradiotherapy were considered dose limiting toxicities.

Time frame:
Day 1 up to 6 weeks or maximum tolerated dose
Reported as:
Count of participants · Participants
Number of Participants With BIO 300 Oral Suspension-related Dose Limiting Toxicity
ParticipantsBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Number of Participants Experiencing DLTs000
Number of Participants That Did Not Experience a DLT677
SecondaryNumber of Participants With Adverse Events Throughout the Study
Time frame:
Day 1 up to month 13 post radiation or 12 months post chemotherapy consolidation for surgical participants.
Reported as:
Number · Participants
Number of Participants With Adverse Events Throughout the Study
ParticipantsBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Number of Participants With Adverse Events Throughout the Study777
SecondaryMean Maximum Serum Concentration (Cmax) of BIO 300 Administered in the Absence of Chemotherapy
Time frame:
Day 1, prior to 1st dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post dose
Reported as:
Mean · ng/mL
Mean Maximum Serum Concentration (Cmax) of BIO 300 Administered in the Absence of Chemotherapy
ng/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Maximum Serum Concentration (Cmax) of BIO 300 Administered in the Absence of Chemotherapy174 ± 74302 ± 194388 ± 264
SecondaryMean Area Under the Serum Concentration Curve (AUC) of BIO 300 Administered in the Absence of Chemotherapy
Time frame:
Day 1, prior to 1st dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post dose
Reported as:
Mean · ng*hr/mL
Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 Administered in the Absence of Chemotherapy
ng*hr/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 Administered in the Absence of Chemotherapy857 ± 3411493 ± 11231570 ± 883
SecondaryMean Maximum Serum Concentration (Cmax) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin
Time frame:
Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to 1st dose then 0.5, 1, 2, 3, 4, 8, and 24 hours post dose
Reported as:
Mean · ng/mL
Mean Maximum Serum Concentration (Cmax) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin
ng/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Maximum Serum Concentration (Cmax) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin155 ± 30427 ± 339414 ± 257
SecondaryMean Area Under the Serum Concentration Curve (AUC) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin
Time frame:
Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to 1st dose then 0.5, 1, 2, 3, 4, 8, and 24 hours post dose
Reported as:
Mean · ng*hr/mL
Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin
ng*hr/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin1371 ± 11741578 ± 7261821 ± 964
SecondaryMean Maximum Serum Concentration (Cmax) of Paclitaxel When Administered in Combination With BIO 300
Time frame:
Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Reported as:
Mean · ng/mL
Mean Maximum Serum Concentration (Cmax) of Paclitaxel When Administered in Combination With BIO 300
ng/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Maximum Serum Concentration (Cmax) of Paclitaxel When Administered in Combination With BIO 300665.5 ± 588.061026.5 ± 260.36307.6 ± 288.2
SecondaryMean Area Under the Serum Concentration Curve (AUC) of Paclitaxel When Administered in Combination With BIO 300
Time frame:
Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Reported as:
Mean · ng*hr/mL
Mean Area Under the Serum Concentration Curve (AUC) of Paclitaxel When Administered in Combination With BIO 300
ng*hr/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Area Under the Serum Concentration Curve (AUC) of Paclitaxel When Administered in Combination With BIO 3001236.51 ± 680.631796.1 ± 409.49755.27 ± 306.45
SecondaryMean Maximum Serum Concentration (Cmax) of Carboplatin When Administered in Combination With BIO 300
Time frame:
Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Reported as:
Mean · ng/mL
Mean Maximum Serum Concentration (Cmax) of Carboplatin When Administered in Combination With BIO 300
ng/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Maximum Serum Concentration (Cmax) of Carboplatin When Administered in Combination With BIO 3007594 ± 1946.039938.33 ± 3452.5812883.33 ± 7446.87
SecondaryMean Area Under the Serum Concentration Curve (AUC) of Carboplatin When Administered in Combination With BIO 300
Time frame:
Week1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Reported as:
Mean · ng*hr/mL
Mean Area Under the Serum Concentration Curve (AUC) of Carboplatin When Administered in Combination With BIO 300
ng*hr/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Mean Area Under the Serum Concentration Curve (AUC) of Carboplatin When Administered in Combination With BIO 30030810.04 ± 5729.841785.18 ± 11133.841753.3 ± 14462.78
SecondaryPercent Change From Baseline in Expression Levels of Serum TGF-beta Isoform 1 (TGFB1)

Measuring change from baseline (screening visit) of TGF-beta isoform 1 (TGFB1)

Time frame:
Screening, once weekly during weeks 1-6 of concurrent chemoradiotherapy prior to BIO 300, paclitaxel, and carboplatin dose, and once at the end of consolidation, 3 months and 6 months after the completion of RT
Reported as:
Mean · Percent change from baseline
Percent Change From Baseline in Expression Levels of Serum TGF-beta Isoform 1 (TGFB1)
Percent change from baselineBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Week 1141.8 ± 64.196.7 ± 5.1117.3 ± 48.5
Week 2130.3 ± 79.9127.5 ± 77.996.7 ± 38.8
Week 3108.6 ± 79.060.1 ± 40.174.4 ± 25.9
Week 490.6 ± 66.069.0 ± 43.855.8 ± 19.9
Week 588.5 ± 86.861.7 ± 44.351.2 ± 12.1
Week 6142.8 ± 133.969.3 ± 43.933.4 ± 33.5
After consolidation therapy68.7 ± 44.274.3 ± 78.560.8 ± 28.4
3 months post-RT205.7 ± 161.2144.9 ± 96.483.1 ± 18.7
6 months post-RT106.5 ± 57.4130.5 ± 93.561.2 ± 36.6
SecondaryRate of Progressive Disease Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) (1.1) Criteria

Best Response Rate reported per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by chest CT imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), At least a 20% increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Screening, visits 20, 37, 38, 39, 40, 41 & 42 (through visit 41 for surgical participants)
Reported as:
Count of participants · Participants
Rate of Progressive Disease Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) (1.1) Criteria
ParticipantsBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Complete Response022
Partial Response522
Stable Disease133
Progressive Disease000
SecondaryChange in Tumor Diameter as Measured by Diagnostic Computerized Tomography (CT) Scan

Tumor diameter was measured in centimeters. Mean change in tumor diameter from the baseline measurement at screening is reported.

Time frame:
Screening, visits 20 and 3, 6, 11 & 13 months post radiation therapy
Reported as:
Mean · Mean Change from Baseline (cm)
Change in Tumor Diameter as Measured by Diagnostic Computerized Tomography (CT) Scan
Mean Change from Baseline (cm)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Visit 20-1.30 ± 1.200.04 ± 3.24-1.15 ± 1.63
3 Months Post-RT-2.83 ± 1.35-2.29 ± 0.82-3.54 ± 1.86
6 Months Post-RT-2.43 ± 0.99-3.23 ± 1.02-3.42 ± 2.08
9 Months Post-RT-2.58 ± 0.87-3.25 ± 0.49-5.0 ± 1.75
11 Months Post-RT-2.55 ± 0.95-3.10 ± 0.56-5.9 ± 0
13 Months Post-RT-2.33 ± 1.31-3.13 ± 1.27-3.05 ± 5.02
SecondaryDLCO as Measured by Pulmonary Function Test (PFT)
Time frame:
Screening and months 6 & 13 post radiation therapy completion
Reported as:
Mean · mL/mmHg/Min
DLCO as Measured by Pulmonary Function Test (PFT)
mL/mmHg/MinBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Baseline12.12 ± 3.8014.96 ± 3.2816.15 ± 6.60
6 months post-RT10.83 ± 4.3110.46 ± 4.2711.28 ± 5.82
13 months post-RT11.65 ± 4.619.48 ± 1.9218.95 ± 1.09
SecondaryNumber of Participants With Pulmonary Fibrosis Assessed by Four-dimensional Computerized Tomography (4D-CT)
Time frame:
Screening, visits 20 & 37 and 9 & 13 months post radiation therapy for non-surgical participants; screening only for surgical participants
Reported as:
Count of participants · Participants
Number of Participants With Pulmonary Fibrosis Assessed by Four-dimensional Computerized Tomography (4D-CT)
ParticipantsBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Number of Participants With Pulmonary Fibrosis Assessed by Four-dimensional Computerized Tomography (4D-CT)000
SecondaryQuality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) Patient Reported Outcome Questionnaire.

The Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) questionnaire is a 36-item self-reporting instrument that measures quality of life specific to patients with cancer. Items are rated on a 5 item (point) Likert Scale, from 0 (not at all) to 4 (very much). Total scores range from 0 to 136 and higher scores indicate better quality of life. The FACT-L TOI questionnaire was scored according to FACT-L Scoring Guidelines Version 4.

Time frame:
Screening and months 3, 6, & 13 post radiation therapy completion
Reported as:
Mean · FACT-L Total Score
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) Patient Reported Outcome Questionnaire.
FACT-L Total ScoreBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Screening66.6 ± 10.853.8 ± 21.553.9 ± 13.2
3 months post-RT54.5 ± 16.463.0 ± 6.755.6 ± 13.3
6 months post-RT55.4 ± 15.549.7 ± 13.551.4 ± 15.0
13 months post-RT50.8 ± 22.461.5 ± 18.155.0 ± 13.8
SecondaryQuality of Life (QOL) as Measured by University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Patient Reported Outcome Questionnaire.

The UCSD-SOBQ is a 24-item patient self-reported questionnaire where items are scored on a 6-point scale (0, "not at all" to 5, "maximal or unable to-do because of breathlessness"). Total scores range from 0 to 120 and lower scores indicate better quality of life.

Time frame:
Screening and months 3, 6, & 13 post radiation therapy completion
Reported as:
Mean · UCSD-SOBQ Total Score
Quality of Life (QOL) as Measured by University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Patient Reported Outcome Questionnaire.
UCSD-SOBQ Total ScoreBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Screening19.4 ± 17.429.9 ± 32.313.9 ± 11.9
3 months post-RT37.0 ± 33.538.0 ± 13.923.0 ± 20.8
6 months post-RT46.8 ± 31.154.7 ± 26.624.8 ± 20.8
13 months post-RT64.0 ± 43.639.8 ± 23.423.2 ± 18.0
SecondaryExtent of Esophagitis by Patient Reported Swallowing Diary

The assessment will provide a score (the swallowing questionnaire) from 0 to 5; 1 no problems swallowing; 2 mild soreness only; 3 some difficulty swallowing solids; 4 cannot swallow solids; and 5 cannot swallow liquids.

Time frame:
Screening, weeks 1, 2, 3, 4, 5, & 6 and months 3 & 6 post radiation therapy completion
Reported as:
Mean · Swallowing Diary Score
Extent of Esophagitis by Patient Reported Swallowing Diary
Swallowing Diary ScoreBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Weeks 1-6 Average1.2 ± 0.361.54 ± 0.411.64 ± 0.87
3 months post-RT1.0 ± 01.0 ± 01.6 ± 0.89
6 months post-RT1.33 ± 0.581.0 ± 01.6 ± 0.55
SecondaryMean Weekly BIO 300 Trough Levels, Serum Concentration of BIO 300
Time frame:
Concurrent chemoradiotherapy weeks 1, 2, 3, 4, 5 and 6
Reported as:
Mean · ng/mL
Mean Weekly BIO 300 Trough Levels, Serum Concentration of BIO 300
ng/mLBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Week 144.2 ± 90.0—16.02 ± 23.7
Week 232.6 ± 44.25.84 ± 8.89.96 ± 13.9
Week 35.1 ± 4.55.56 ± 8.014.12 ± 18.6
Week 48.3 ± 13.93.82 ± 6.022.66 ± 44.7
Week 540.7 ± 36.26.71 ± 11.923.54 ± 38.0
Week 612.4 ± 15.724.0 ± 32.524.54 ± 23.8
SecondaryWeekly Paclitaxel Trough Levels, Plasma Concentration of Paclitaxel and Carboplatin

Serum trough levels of paclitaxel and carboplatin were measured. Carboplatin trough levels were below the limit of quantification at all timepoints and are therefore reported as NA (Not Available).

Time frame:
Concurrent chemoradiotherapy weeks 1, 2, 3, 4, 5 and 6
Reported as:
Mean · ng/mL
Weekly Paclitaxel Trough Levels, Plasma Concentration of Paclitaxel and Carboplatin
ng/mLPaclitaxelCarboplatin
Week 11.04 ± 0.08NA ± NA
Week 21.09 ± 0.19NA ± NA
Week 31.53 ± 0.93NA ± NA
Week 41.83 ± 0.81NA ± NA
Week 51.90 ± 0.96NA ± NA
Week 61.92 ± 1.19NA ± NA
SecondaryFVC as Measured by Pulmonary Function Test (PFT)
Time frame:
Screening and months 6 & 13 post radiation therapy completion
Reported as:
Mean · Liters
FVC as Measured by Pulmonary Function Test (PFT)
LitersBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Baseline2.46 ± 0.462.79 ± 0.563.51 ± 0.85
6 months post-RT2.32 ± 0.652.1 ± 0.602.93 ± 0.74
13 months post-RT2.32 ± 0.672.19 ± 0.443.28 ± 0.27
SecondaryFEV1 as Measured by Pulmonary Function Test (PFT)
Time frame:
Screening and months 6 & 13 post radiation therapy completion
Reported as:
Mean · Liters
FEV1 as Measured by Pulmonary Function Test (PFT)
LitersBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
Baseline1.69 ± 0.381.91 ± 0.592.39 ± 0.83
6 months post-RT1.71 ± 0.531.29 ± 0.132.03 ± 0.60
13 months post-RT1.61 ± 0.551.26 ± 0.062.39 ± 0.27

Adverse events

Collected over Day 1 up to month 13 post radiation or 12 months post chemotherapy consolidation for surgical participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BIO 300 Oral Suspension (500 mg/Day)2/7 (28.6%)3/7 (42.9%)7/7 (100%)
BIO 300 Oral Suspension (1000 mg/Day)0/7 (0%)1/7 (14.3%)7/7 (100%)
BIO 300 Oral Suspension (1500 mg/Day)1/7 (14.3%)2/7 (28.6%)7/7 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
DyspneaRespiratory, thoracic and mediastinal disorders1/70/72/7
Atrial FibrillationCardiac disorders0/70/71/7
Cardiac ArrestCardiac disorders1/70/70/7
Sinus TachycardiaCardiac disorders0/71/70/7
DiarrheaGastrointestinal disorders1/70/70/7
FeverGeneral disorders0/70/71/7
CoughRespiratory, thoracic and mediastinal disorders0/70/71/7
Thromboembolic EventVascular disorders1/70/71/7
EsophagitisGastrointestinal disorders0/70/71/7
DehydrationMetabolism and nutrition disorders0/70/71/7
Most frequent other events
Showing 10 of 38
Most frequent other events
EventBIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)
EsophagitisGastrointestinal disorders0/75/77/7
White Blood Cell DecreasedInvestigations1/76/72/7
Neutrophil Count DecreasedInvestigations3/75/71/7
Platelet Count DecreasedInvestigations2/75/72/7
FatigueGeneral disorders2/73/74/7
Radiation DermatitisInjury, poisoning and procedural complications1/72/74/7
Lymphocyte DecreasedInvestigations0/74/73/7
PneumonitisRespiratory, thoracic and mediastinal disorders1/74/73/7
ConstipationGastrointestinal disorders2/73/71/7
DysphagiaGastrointestinal disorders2/72/73/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
Median78 (69 to 84)69 (57 to 83)57 (50 to 76)69 (50 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
Female55111
Male22610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
Hispanic or Latino1203
Not Hispanic or Latino65718
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White67619
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
United States77721
Initial Tumor Stage
Initial Tumor Stage(Participants)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
Stage II2215
Stage III55414
Stage IV0022
Tumor Histology
Tumor Histology(Participants)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
Squamous33410
Adenocarcinoma44311
Primary Tumor Location
Primary Tumor Location(Participants)BIO 300 Oral Suspension (500 mg/Day)BIO 300 Oral Suspension (1000 mg/Day)BIO 300 Oral Suspension (1500 mg/Day)Total
Left Upper Lobe3317
Left Lower Lobe0123
Right Upper Lobe3249
Right Middle Lobe0101
Right Lower Lobe1001
08

Study locations

4 sites
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202-2689, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Zablocki VA Medical Center
    Milwaukee, Wisconsin 53295, United States
09

References and documents

Publications

  • Simone CB 2nd, Serebrenik AA, Gore EM, Mohindra P, Brown SL, Wang D, Chetty IJ, Vujaskovic Z, Menon S, Thompson J, Fine G, Kaytor MD, Movsas B. Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):404-414. doi: 10.1016/j.ijrobp.2023.08.048. Epub 2023 Aug 29. Erratum In: Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):1029. doi: 10.1016/j.ijrobp.2024.02.009. PubMed 37652301 ↗
  • Citrin DE, Prasanna PGS, Walker AJ, Freeman ML, Eke I, Barcellos-Hoff MH, Arankalayil MJ, Cohen EP, Wilkins RC, Ahmed MM, Anscher MS, Movsas B, Buchsbaum JC, Mendonca MS, Wynn TA, Coleman CN. Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. Radiat Res. 2017 Jul;188(1):1-20. doi: 10.1667/RR14784.1. Epub 2017 May 10. PubMed 28489488 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Apr 2019 and a completion of Sep 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2023, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2015
First posted
Oct 5, 2015
Start
Nov 2015
Primary completionActual
Apr 2019
CompletionActual
Sep 2020
Results first posted
Dec 20, 2023
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02567799
Lead sponsor
Humanetics Corporation
Responsible party
Sponsor
First posted
Oct 5, 2015
Start date
Nov 2015
Primary completion
Apr 2019
Completion
Sep 2020
Results posted
Dec 20, 2023
Last update
Jan 25, 2024

Study contacts

Michael D. Kaytor, PhD
study director · Humanetics Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Genistein-based BIO 300

Start the discussion